Immunotherapy Combination Treatment Options Growing in R/R Multiple Myeloma SpaceSeptember 25th 2018
Sham Mailankody, MBBS, discusses current treatment options and shifting preferences, especially toward triplet combinations, for patients with relapsed/refractory multiple myeloma, as well as emerging immunotherapy treatment options.
Pushing Ahead With New Treatments for Nonmetastatic Castration-Resistant Prostate CancerSeptember 22nd 2018
Patients with the localized form of CRPC still have no options that are proven to extend overall survival, but preliminary results from the PROSPER trial of enzalutamide and the SPARTAN trial of apalutamide offer them unprecedented hope.
Expert Highlights the Complexities of Novel-Novel Drug Combos in LymphomasSeptember 21st 2018
Combinations of novel drugs used for treating patients with lymphomas may have the potential to improve responses and overcome resistance to therapy but can be accompanied by unexpected adverse events that demand careful monitoring, Kieron Dunleavy, MD, cautioned during the 2018 Pan Pacific Lymphoma Conference.
Targeted Treatments Emerge for HER2 Mutations in Lung CancerSeptember 20th 2018
HER2 mutations have been identified as another oncogenic driver in the growing list of actionable targets in non–small cell lung cancer. Based on a mounting body of evidence on the impact of HER2 mutations in lung cancer and the growing focus on personalized medicine, the HER2 receptor has gained focus as a potential target for precision medicine treatments for patients with NSCLC.
Site-Neutral Payments and a Reformed 340B Program - CMS Proposed Changes for 2019September 20th 2018
Medicare patients could save an estimated $150 million on out-of-pocket co-payments for clinic visits if proposed changes to the hospital Outpatient Prospective Payment System and Ambulatory Surgical Cancer payment system are adopted by the Centers for Medicare & Medicaid Services for 2019.
ACCC Forum Offers Sustainable Solutions for Tackling BurnoutSeptember 20th 2018
Increased focus has been placed on the overwhelming stress within the physician community, often referred to as burnout. According to Medscape’s 2018 National Physician Burnout and Depression Report, nearly twothirds of physicians within the United States have reported symptoms.
Novel Agents are Changing the Face of Metastatic TNBCSeptember 19th 2018
Only 1 treatment option is currently available for treating patients with metastatic germline <em>BRCA</em>-mutated triple-negative breast cancer, but research into novel therapies, including PI3K/conjugates could soon result in a host of new therapies for this hard-to-treat disease.
The Impact of CAR T-Cell Therapies in DLBCLSeptember 19th 2018
Quick progress was seen with a novel class of agents, chimeric antigen receptor T-cell therapies, in the setting of diffuse large B-cell lymphoma—a swift jump from early phase clinical trials to FDA-approved products.
SIRT Added to Chemotherapy Extends Survival in Right-Sided Colorectal CancersSeptember 19th 2018
Adding selective internal radiation therapy to chemotherapy improved overall survival by 5 months compared with chemotherapy alone for patients with liver-only or liver-dominant right-sided primary metastatic colorectal cancer, according to results from a post hoc analysis of 2 randomized, controlled trials.
Improving Upon Checkpoint Blockade Responses With Combinations in Hodgkin LymphomaSeptember 18th 2018
Despite progress seen with immune checkpoint inhibitors in Hodgkin lymphoma, there remains an unmet need for greater responses, which could be filled by potential combination approaches, according to Stephen M. Ansell, MD, PhD.
Debating the Standard of Care for Resectable Colorectal Cancer Liver MetsSeptember 18th 2018
Two oncologists from the Winship Cancer Institute of Emory University reviewed data for and against the use of chemotherapy for patients with resectable colorectal cancer liver metastases. Mehmet Akce, MD, spoke in favor of chemotherapy, while Shishir K. Maithel, MD, argued against it.
Are Adjuvant TKIs in High-Risk RCC Ready for Prime Time?September 17th 2018
Long-term metastatic control is an important goal for patients with high-risk renal cell carcinoma after nephrectomy. In recent years, adjuvant therapy with tyrosine kinase inhibitors has entered the picture to potentially fill this unmet need.